NEOADJUVANT THERAPY
Clinical trials for NEOADJUVANT THERAPY explained in plain language.
Never miss a new study
Get alerted when new NEOADJUVANT THERAPY trials appear
Sign up with your email to follow new studies for NEOADJUVANT THERAPY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy-Chemo cocktail shows promise for shrinking cervical tumors before surgery
Disease control Not yet recruitingThis phase II trial is testing whether adding an immunotherapy drug (QL1706) to standard chemotherapy before surgery can help shrink tumors in women with early-stage cervical cancer (stages IB1-IB3). About 50 participants will receive the combination, then undergo conservative su…
Matched conditions: NEOADJUVANT THERAPY
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New targeted pill could boost lung cancer surgery success
Disease control Not yet recruitingThis phase II trial is testing whether the targeted therapy firmonertinib, taken as a pill for 8 to 16 weeks before surgery, can shrink tumors in people with stage II-IIIB EGFR-mutated lung adenocarcinoma. About 60 participants will receive the drug and then undergo surgery to re…
Matched conditions: NEOADJUVANT THERAPY
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Pill form chemo shows promise for older lung cancer patients in new trial
Disease control Not yet recruitingThis study tests an oral chemotherapy (paclitaxel) combined with immunotherapy given before surgery in patients aged 70-85 with non-small cell lung cancer. The goal is to see if this approach can shrink tumors enough to improve surgery outcomes and long-term survival. About 75 pa…
Matched conditions: NEOADJUVANT THERAPY
Phase: NA • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Lung cancer breakthrough: could observation replace surgery?
Disease control Not yet recruitingThis pilot study tests whether it is safe and feasible to skip surgery in patients with stage II-III non-small cell lung cancer who have a complete response to chemotherapy and immunotherapy. Fourteen participants will be randomly assigned to either observation or standard surger…
Matched conditions: NEOADJUVANT THERAPY
Phase: PHASE1 • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug cocktail shows promise in shrinking esophageal tumors before surgery
Disease control Not yet recruitingThis phase 2 trial will test whether adding the experimental drug ivonescimab to standard chemotherapy before surgery can improve outcomes for people with resectable esophageal squamous cell carcinoma. About 49 participants will receive three cycles of the combination, then under…
Matched conditions: NEOADJUVANT THERAPY
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail aims to shrink esophageal tumors before surgery
Disease control Not yet recruitingThis study tests whether a combination of three drugs (camrelizumab, chemotherapy, and ivarmacitinib) given before surgery can help people with a type of esophageal cancer. The goal is to see if the treatment can eliminate or shrink the tumor enough to improve surgical outcomes. …
Matched conditions: NEOADJUVANT THERAPY
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New study aims to spare breast cancer patients from chemo and major surgery
Disease control Not yet recruitingThis study tests a new approach for women with a common type of early breast cancer (HR+/HER2-). Instead of standard chemotherapy before surgery, some participants will receive a combination of hormone therapy and a targeted drug (abemaciclib) based on their tumor's gene test res…
Matched conditions: NEOADJUVANT THERAPY
Phase: PHASE2 • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New breast cancer trial aims to spare heart toxicity with smart drug strategy
Disease control Not yet recruitingThis Phase 2 trial tests a new antibody drug (QL1706) combined with chemotherapy in 40 people with early triple-negative breast cancer. The treatment is tailored based on how the tumor responds after initial cycles, with the goal of avoiding certain heart-damaging drugs if possib…
Matched conditions: NEOADJUVANT THERAPY
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Promising drug duo targets Hard-to-Treat HER2 cancers
Disease control Not yet recruitingThis study tests two drugs, zanidatamab and tislelizumab, combined with standard chemo or radiation for people with HER2-positive stomach or colorectal cancers. About 70 adults aged 18-75 will receive the treatment to see if it shrinks tumors and controls the disease. The goal is…
Matched conditions: NEOADJUVANT THERAPY
Phase: PHASE2 • Sponsor: Tao Zhang • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Immunotherapy plus chemo shows promise for pancreatic cancer before surgery
Disease control Not yet recruitingThis phase 2 trial is testing whether adding the immunotherapy drug adebrelimab to standard chemotherapy can help shrink pancreatic tumors before surgery. About 30 people with resectable pancreatic cancer will receive the combination, and researchers will measure how many tumors …
Matched conditions: NEOADJUVANT THERAPY
Phase: PHASE2 • Sponsor: Jinling Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug duo aims to shrink aggressive breast cancer before surgery
Disease control Not yet recruitingThis phase 2 trial tests a combination of two drugs—sacituzumab tirumotecan and pembrolizumab—given before surgery to people with stage II or III triple-negative breast cancer. The goal is to see if the treatment can completely eliminate the cancer by the time of surgery. The stu…
Matched conditions: NEOADJUVANT THERAPY
Phase: PHASE2 • Sponsor: Yantai Yuhuangding Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Family power: exercise and nutrition program may cut surgery complications in stomach cancer
Disease control Not yet recruitingThis study tests whether a family-supervised program combining exercise, nutrition advice, and psychological support can reduce complications after stomach cancer surgery. About 90 adults who will receive chemotherapy before surgery are randomly assigned to either the program plu…
Matched conditions: NEOADJUVANT THERAPY
Phase: NA • Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control
Last updated Jun 26, 2026 18:50 UTC
-
New pill may shrink lung tumors before surgery in Gene-Mutated cancers
Disease control Not yet recruitingThis phase 2 trial tests the drug Vebreltinib, taken as a pill for 8 weeks before surgery, in 30 people with stage IIA-IIIB non-small cell lung cancer that has a specific gene change (MET exon 14 skipping). The goal is to see if the drug can shrink tumors enough to improve surger…
Matched conditions: NEOADJUVANT THERAPY
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 26, 2026 13:55 UTC
-
Simple glove trick may shield nerves during chemo
Prevention Not yet recruitingThis study tests whether wearing a tight surgical glove on one hand during chemotherapy can prevent nerve damage (peripheral neuropathy) in breast cancer patients. 44 participants will wear a smaller glove on their dominant hand during each chemo session, while the other hand ser…
Matched conditions: NEOADJUVANT THERAPY
Phase: NA • Sponsor: Jinsong Lu • Aim: Prevention
Last updated Jun 26, 2026 15:53 UTC
-
AI could revolutionize esophageal cancer care: 7,000-Patient study launches
Knowledge-focused Not yet recruitingThis study aims to develop an AI system that helps doctors choose the best treatment for esophageal cancer. Researchers will collect data from 7,000 patients, including medical images and tissue samples, to train a computer model that predicts how well a patient will respond to t…
Matched conditions: NEOADJUVANT THERAPY
Sponsor: Henan Cancer Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC